Efficacy refers to the maximum effect a drug can produce, regardless of the dose. Drug B produces a greater maximal diuresis (4 L) than Drug A (2 L), so it has higher efficacy. Potency refers to the amount of drug needed to produce a given effect (often measured by ED50). Drug B requires a higher dose (40 mg) to achieve 50% of its maximal effect compared to Drug A (20 mg), indicating it has lower potency. Therefore, Drug B has lower potency but higher efficacy than Drug A.

Buprenorphine is a partial agonist at the μ-opioid receptor. This means it binds to the receptor and produces a submaximal response (lower efficacy than full agonists like morphine). This property provides relief from cravings and withdrawal without causing the same degree of euphoria and respiratory depression. However, because it has high affinity for the receptor, it can displace full agonists like morphine. When it displaces morphine, the overall receptor stimulation decreases, leading to a net reduction in effect and precipitating withdrawal symptoms.

An inverse agonist binds to the same receptor as an agonist but elicits the opposite pharmacological response. In systems with constitutive (basal) activity, an inverse agonist reduces this activity below the baseline level. Drug X is an agonist, as it increases activity. Drug Y is a neutral antagonist, as it blocks the agonist but has no effect on its own. Drug Z is an inverse agonist because it reduces the receptor's activity below the constitutive level.

This phenomenon describes the concept of spare receptors. A system has spare receptors when a maximal pharmacologic response can be elicited by an agonist at a concentration that does not occupy all available receptors. This indicates a high degree of coupling between receptor activation and downstream signaling pathways. This is common for hormones like insulin and for catecholamines acting on β-adrenergic receptors. Partial agonism would result in a submaximal response. Downregulation is a decrease in receptor number over time. Competitive antagonism would inhibit the response.

The median effective dose (ED50) is the dose at which 50% of individuals in a population exhibit a specified quantal (all-or-none) effect. In this trial, the specified effect is achieving a target HbA1c < 7.0%. Since 250 out of 500 patients (50%) achieved this effect at a dose of 50 mg, this dose represents the ED50. LD50 and TD50 refer to lethal and toxic doses, respectively. Emax refers to the maximal response, not a population-based dose.

Potency refers to the concentration or dose of a drug required to produce 50% of its maximal effect. Since Drug X has a lower ED50 (10 mg) compared to Drug Y (50 mg), it is more potent. Efficacy is the maximal effect a drug can produce. The passage states that both drugs produce the same maximal effect, so their efficacies are equal. There is not enough information to determine if Drug X is a partial agonist or to compare their therapeutic indices.

Metoprolol is a competitive antagonist. Competitive antagonists bind reversibly to the same site as the agonist (epinephrine). This increases the concentration of agonist required to produce a given effect, shifting the dose-response curve to the right (decreasing potency). However, because the binding is reversible, the antagonism can be overcome by adding more agonist. Therefore, the maximal effect (efficacy) is not changed. A noncompetitive antagonist would decrease the maximal effect.

The therapeutic index (TI) is calculated as TD50 / ED50. In this case, TI = 200 mg/kg / 20 mg/kg = 10. A higher therapeutic index indicates a wider margin between the dose that produces a therapeutic effect and the dose that causes toxicity. Therefore, a TI of 10 suggests a relatively high (or wide) margin of safety, meaning that an overdose is less likely to occur with standard dosing adjustments compared to a drug with a TI of 2.

Nalbuphine is a mixed agonist-antagonist opioid. It is an antagonist at μ-receptors and an agonist at κ-receptors. When given to a patient who is physically dependent on a full μ-agonist like morphine, nalbuphine competitively displaces morphine from the μ-receptors. Because nalbuphine has no agonist activity (or much lower intrinsic activity) at the μ-receptor, this displacement causes a rapid decrease in receptor stimulation, precipitating an acute withdrawal syndrome. This demonstrates that a partial agonist or antagonist can reverse the effects of a full agonist.

Steroid hormones, such as glucocorticoids (e.g., hydrocortisone), are lipophilic molecules that can easily cross the cell membrane. Their receptors are intracellular, located primarily in the cytoplasm. Upon binding the hormone, the receptor-hormone complex undergoes a conformational change, translocates to the nucleus, and acts as a transcription factor by binding to specific DNA sequences (glucocorticoid response elements) to modify gene expression.